NFE2L2 and cancer: It has been determined that certain cancer forms contain mutations in metabolic enzymes, such as TP53, retinoblastoma protein (Rb), and HIF‐1α, as well as enzymes like hexokinase (HK), pyruvate kinase isozymes M2 (PKM2), isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), and nicotinamide phosphoribosyl transferase (Nampt), CDKN2A, or activating mutations of NFE2L2, NOTCH1/2, MLL2, and EP300 [48] driving tumor progression and metastasis [49, 50].